Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 94-101

  Itagaki, Mai ^a,b   Takaguri, Akira ^a   Kano, Seiichiro ^a   Kaneta, Shigeru ^a   Ichihara, Kazuo ^a   Satoh, Kumi ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cell death; Geranylgeranylation; L6 fibroblasts; Skeletal muscle toxicity; Statin

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CASPASE 3; CREATINE KINASE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PRAVASTATIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOSOL; CYTOTOXICITY; ENZYME ACTIVATION; FIBROBLAST; HYDROPHOBICITY; IN VIVO STUDY; MALE; MUSCLE TOXICITY; NONHUMAN; PROTEIN LOCALIZATION; RAT; SKELETAL MUSCLE;

EID: 58649111741     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08238FP     Document Type: Article

References (23)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
2. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711- 1718.
3. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
4. FDA talk paper. Bayer voluntarily withdraws Baycol on August 2001.
5. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, et al. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. J Atheroscler Thromb. 2006;13:295-307.
6. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237.
7. Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol. 2006;149:909-919.
8. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 2005;57:1475-1484.
9. Driks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:C1208-C1212.
10. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62:1709-1712.
11. Goldstein L, Brown S. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
12. Hughes D. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. J Hum Hypertens. 1996;10:387-390.
13. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci. 2008;107:80-89.
14. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull. 1996;19:1518-1520.
15. Miller T, Beausang LA, Meneghini M, Lidgard G. Death- induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis. Biotechniques. 1993;15:1042-1047.
16. Tang H, Guo DF, Porter JP, Wanaka Y, Inagami T. Role of cytoplasmic tail of the type 1A angiotensin II receptor in agonist- and phorbol ester-induced desensitization. Circ Res. 1998;82:523-531.
17. Al-Rawithi S, Hussein RF, Alzahrani A. Sensitive assay for the determination of fluvastatin in plasma utilizing high- performance liquid chromatography with fluorescence detection. Ther Drug Monit. 2003;25:88-92.
18. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis. 2003;170:237-243.
19. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta. 1990;1045:115-120.
20. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet. 2002; 359:2195-2198.
21. Yamazaki M, Suzuki H, Hanano M, Tokui T, Kamai T, Sugiyama Y. Sodium-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993;264:36-44.
22. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rabsmall GTPases are involved in fluvastatin and pravastatin- induced vacuolation in rat skeletal myofibers. FASEB J. 2007;21:4087-4094.
23. Vu D, Murty M, McMorran M. Statins: rhabdomyolysis and myopathy. CMAJ. 2002;166:85-86.